Albert David Limited (ADL), incorporated in 1938, stands as a prominent pharmaceutical manufacturing company based in Kolkata. The company operates as part of the renowned Kothari Group, one of Kolkata's established industrial houses. With over eight decades of operational experience, Albert David has established itself as a significant player in India's pharmaceutical sector, maintaining its headquarters in Kolkata, West Bengal.
The company's leadership includes Chairman Arun Kumar Kothari and Managing Director Umesh Manohar Kunte. The registered office is located at D Block 3rd Floor Gillander House, Netaji Subhas Road, Kolkata, West Bengal-700001. ADL has built a strong foundation over the decades, becoming synonymous with quality pharmaceutical products and innovative healthcare solutions.
Albert David's principal business involves manufacturing and trading pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs for both domestic sales and export markets. Beyond its core pharmaceutical products, the company also manufactures disposable syringes, needles, and maintains a comprehensive range of bulk drugs.
The company's formulation portfolio encompasses:
- Parenterals
- Oral/enteral preparations
- Topical agents
- Vision care products
Notable product ranges include the Placentrex range, Anaflam range, and BREAZE range, which have established strong market presence across various therapeutic segments.
Albert David has gained recognition as a significant IV fluid manufacturer, producing solutions in both glass and polyethylene containers. This specialization has positioned the company as a reliable supplier in the critical care and hospital segment, where intravenous solutions play a vital role in patient treatment.
The company has established a notable international presence, exporting its products to Latin American countries, Southeast Asian markets, and various African nations. This global reach demonstrates Albert David's commitment to quality and compliance with international pharmaceutical standards, enabling the company to compete in diverse regulatory environments worldwide.
The export business provides the company with revenue diversification and reduces dependence on domestic market fluctuations. This international exposure also brings valuable experience in meeting stringent quality requirements demanded by different countries' regulatory authorities.
Albert David has established strategic partnerships with prestigious academic institutions for research outsourcing, including:
- The Indian Institute of Chemical Biology (CSIR)
- The Department of Biotechnology at Calcutta University
These collaborations enable the company to leverage cutting-edge research capabilities and stay at the forefront of pharmaceutical innovation.
The company has entered into a technical collaboration with Morishita Pharmaceuticals, Japan (a subsidiary of Ajinomoto), to manufacture amino acid infusions. This international partnership demonstrates Albert David's commitment to adopting advanced technologies and expanding its product portfolio with specialized pharmaceutical solutions.
Albert David has established a manufacturing unit in Kalyani, West Bengal, specifically for bulk drug production, which became operational in 1990. This facility expansion reflects the company's strategic approach to vertical integration and its commitment to controlling the entire value chain from raw materials to finished products.
The company's manufacturing capabilities span multiple product categories, ensuring operational flexibility and the ability to respond to changing market demands. The infrastructure supports both domestic and international quality standards, enabling the company to serve diverse markets effectively.
As of May 15, 2025, Albert David Ltd maintains a market capitalisation of ₹473 crores, positioning it as a small-cap company in the pharmaceutical sector.
Key Financial Metrics:
- Market Capitalisation: ₹473 crores (As of May 15, 2025)
- Revenue: ₹346 crores _(Specific time period requires clarification from recent financial statements)_
- Profit: ₹17.2 crores _(Specific time period requires clarification from recent financial statements)_
- TTM Profit After Tax: ₹17 crores
- Return on Equity: 12.5% (over last 3 years)
- Dividend Declared: ₹11.50 per share (for March 2024 quarter)
The company experienced challenges in Q4 2024-2025, reporting a net loss of ₹10.33 crores compared to a net profit of ₹12.91 crores in the previous year. This performance indicates some operational challenges that the company needs to address going forward.
- Promoter Holding: 62.24% (As of March 2025)
- Mutual Fund Holding: Minimal at 0.01% (As of May 15, 2025)
Promoter holding in Albert David Ltd stands at 62.24%, indicating strong promoter commitment and a stable ownership structure. The company maintains a clean capital structure with no promoter pledging, which reflects good corporate governance practices and financial discipline. The minimal mutual fund shareholding suggests limited institutional investor participation, presenting potential opportunities for increased institutional interest as the company's fundamentals improve.
- P/B Ratio: 1.20 times (As of May 15, 2025) - Represents a 79% discount to its peers' median range of 5.69 times.
- P/E Ratio: 27.47 times - Shows a 23% discount to the industry median of 35.84 times.
- Debt Status: Almost debt-free, providing financial flexibility and reducing interest burden.
- Sales Growth (5-year): Modest at 1.57%, indicating the need for strategic initiatives to accelerate growth momentum.
Albert David Limited represents a well-established pharmaceutical company with a rich heritage and diverse product portfolio. While facing recent performance challenges, the company's strong promoter backing, debt-free status, and established market presence provide a solid foundation for potential recovery and growth in India's expanding pharmaceutical market.
